Intravascular Stents Market: as MicroPort Coronary crosses 10 million cumulative global stent shipments and implantations, the milestone confirms that domestic Chinese drug-eluting stent manufacturing has reached genuine global scale, not just domestic market share, so established Western manufacturers can no longer treat Chinese and other emerging-market competitors as regional players to be managed at arm's length, and the competitive map for coronary stents now includes at least one non-Western manufacturer operating at a volume comparable to the category's historical leaders.

The global intravascular stents market size was USD 12.64 Billion in 2025 and is expected to register a revenue CAGR of 5.8% during the forecast period. Market revenue growth is driven by factors such as sustained global cardiovascular disease burden requiring coronary intervention, next-generation drug-eluting stent platforms improving polymer technology for faster endothelial healing, and domestic Chinese stent manufacturers reaching global cumulative production and clinical adoption milestones. The first driving factor is sustained global cardiovascular disease burden, with the World Health Organization documenting approximately 17.9 million annual cardiovascular disease deaths worldwide. Drug-eluting stents account for approximately 88% of total 2025 coronary stent revenue share, reflecting the technology's continued dominance over bare metal alternatives. The second driving factor is next-generation drug-eluting stent platforms improving polymer technology specifically to accelerate endothelial healing and reduce thrombosis risk relative to earlier stent generations. The third driving factor is domestic Chinese stent manufacturers reaching global cumulative production and clinical adoption milestones that confirm manufacturing scale comparable to established Western manufacturers. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way cumulative global shipment and implantation milestones function as a credibility signal that converts a manufacturer's growing production scale into expanded international market access, particularly in emerging markets where hospital purchasing committees weigh a manufacturer's demonstrated track record heavily in procurement decisions. Because hospital purchasing committees in markets outside a stent manufacturer's home country often weigh cumulative clinical usage and manufacturing scale as a proxy for reliability and quality when detailed long-term outcome data is not yet as extensive as for the most established Western platforms, a manufacturer crossing a major cumulative shipment milestone gains a credibility signal that directly supports its international expansion into new emerging-market hospital systems. As a result, demand and revenue share are concentrating around manufacturers who can combine genuine manufacturing scale with international market access, and the forecast reflects domestic Chinese and other emerging-market manufacturer international expansion as a distinct driver of competitive structure independent of any single new platform launch. For instance, in October 2025, MicroPort Coronary's cumulative global stent shipments and implantations each surpassed 10 million units, a milestone the company positioned as confirming its position as a domestic Chinese drug-eluting stent manufacturer operating at genuinely international scale across both domestic and emerging international markets. These are some of the key factors driving revenue growth of the market.

Because domestic Chinese and other emerging-market manufacturers with vertically integrated production and local sourcing can offer meaningfully lower pricing than established Western manufacturers, price competition in high-volume Asian markets continues to compress average selling prices even as underlying procedure volume grows.

Continued clinical caution around bioresorbable scaffold technology is a second constraint, because earlier-generation fully bioresorbable coronary scaffolds faced documented clinical setbacks that have made both physicians and regulators cautious about newer bioresorbable platforms despite their theoretical long-term advantage of leaving no permanent implant behind.

Reimbursement variability across health systems is a third constraint, since coronary and peripheral stent procedure reimbursement rates vary substantially by country and payer, which creates inconsistent adoption of the newest platform generations even where clinical guidelines support their use.

These factors substantially limit intravascular stents market growth over the forecast period.

The clearest driver of demand is the sustained scale of global cardiovascular disease burden, which anchors baseline coronary intervention demand regardless of any single manufacturer's competitive positioning. Coronary artery disease requiring percutaneous intervention represents a large and clinically well-defined patient population, so the underlying demand for coronary stenting tracks global cardiovascular disease incidence and mortality trends directly, independent of which specific stent platform a given patient ultimately receives. Drug-eluting stents account for approximately 88% of total 2025 coronary stent revenue share, and the World Health Organization documents approximately 17.9 million annual cardiovascular disease deaths worldwide, underscoring the scale of the underlying clinical burden. The effect on the market is that baseline stent demand remains structurally resilient, providing a stable revenue floor beneath the market's platform-level and manufacturer-level competitive dynamics. These are some of the key factors driving revenue growth of the market.

The second driver is next-generation drug-eluting stent platforms improving polymer technology specifically to accelerate endothelial healing and reduce late thrombosis risk relative to earlier stent generations. Faster endothelial healing over a stent's struts reduces the window during which a patient remains at elevated thrombosis risk, so a polymer technology improvement that measurably accelerates this healing process addresses one of the most clinically significant long-term risk factors associated with coronary stenting. In January 2025, Medtronic received CE Mark clearance for an improved polymer formulation on its Resolute Onyx drug-eluting stent platform, specifically engineered for faster endothelial healing and lower thrombosis risk, and in March 2025, Abbott announced its next-generation sirolimus-eluting platform with enhanced radiopacity for complex anatomy delivery. The effect on the market is that polymer chemistry improvement continues to be a primary avenue for meaningful clinical differentiation even among already highly established DES platforms. These are some of the key factors driving revenue growth of the market.

MicroPort Coronary's cumulative global stent shipments and implantations each surpassed 10 million units in October 2025. Domestic Chinese drug-eluting stent manufacturing has reached genuinely international scale, not just domestic market presence.

The third driver is domestic Chinese stent manufacturers reaching global cumulative production and clinical adoption milestones that function as a credibility signal supporting expanded international market access. Hospital purchasing committees in markets outside a manufacturer's home country often weigh cumulative clinical usage and manufacturing scale as a meaningful proxy for reliability when extensive long-term outcome data specific to their own patient population is not yet available, so crossing a major cumulative shipment milestone provides tangible evidence of scale that directly supports a manufacturer's case for adoption in new markets. In October 2025, MicroPort Coronary's cumulative global stent shipments and implantations each surpassed 10 million units, a milestone the company positioned as confirming genuinely international manufacturing and clinical adoption scale across both its domestic Chinese base and expanding emerging international markets. The effect on the market is that established Western manufacturers can no longer treat Chinese and other emerging-market stent manufacturers as purely domestic or regional competitors to be managed at arm's length. These are some of the key factors driving revenue growth of the market.

However, the intravascular stents market faces severe adoption constraints from pricing pressure in high-volume Asian markets and continued clinical caution around bioresorbable scaffold technology following earlier-generation setbacks.

Because domestic Chinese and other emerging-market manufacturers with vertically integrated production and local sourcing can offer meaningfully lower pricing than established Western manufacturers, price competition in high-volume Asian markets continues to compress average selling prices even as underlying procedure volume grows, a dynamic reinforced by MicroPort Coronary's expanding international scale.

Continued clinical caution around bioresorbable scaffold technology compounds this, because earlier-generation fully bioresorbable coronary scaffolds faced documented clinical setbacks that have made both physicians and regulators cautious about newer bioresorbable platforms despite their theoretical long-term advantage of leaving no permanent implant behind.

Reimbursement variability across health systems is the third constraint, since coronary and peripheral stent procedure reimbursement rates vary substantially by country and payer, which creates inconsistent adoption of the newest platform generations even where clinical guidelines support their use.

These factors substantially limit intravascular stents market growth over the forecast period.

Based on product, the global intravascular stents market is segmented into coronary stents, peripheral vascular stents, and non-vascular stents. Coronary stents hold the largest revenue share, because coronary artery disease intervention volume dwarfs other stenting application categories globally, which ties directly back to the cardiovascular disease burden described in the market's primary demand driver. Peripheral vascular stents remain an established and growing category for iliac, renal, and superficial femoral artery intervention. Non-vascular stents are expected to register the fastest revenue growth rate in the global intravascular stents market over the forecast period, driven by expanding biliary and ureteral stenting applications in oncology and urology settings.

Based on technology, the global intravascular stents market is segmented into drug-eluting stents, bare metal stents, bioresorbable scaffolds, and covered or stent-graft systems. Drug-eluting stents hold the largest revenue share, accounting for approximately 88% of coronary stent revenue, because they demonstrate superior restenosis prevention compared to bare metal alternatives across the overwhelming majority of clinical indications, which ties directly back to the technology dominance described in the market's primary demand driver. Bioresorbable scaffolds are expected to register the fastest revenue growth rate in the global intravascular stents market over the forecast period from a smaller base, driven by continued clinical research addressing the technology's earlier-generation limitations, which is why manufacturers continue cautious, evidence-driven investment in next-generation bioresorbable platforms.

Based on material, the global intravascular stents market is segmented into stainless steel, cobalt-chromium, and platinum-chromium and nitinol materials. Cobalt-chromium holds the largest revenue share, because it is the base material for the majority of currently marketed thin-strut drug-eluting stent platforms, including Abbott's XIENCE and Boston Scientific's Synergy families, which ties directly back to the DES technology dominance described in the market's primary demand driver. Platinum-chromium and nitinol materials are expected to register the fastest revenue growth rate in the global intravascular stents market over the forecast period, driven by platinum-chromium's superior radiopacity and radial strength at thinner strut profiles for next-generation platform development.

Based on regional analysis, the intravascular stents market in North America accounted for largest revenue share in 2025. The United States leads because the concentration of interventional cardiology procedure volume and FDA regulatory activity creates a direct clinical-to-commercial pathway, and because Abbott, Boston Scientific, and Medtronic all maintain their primary commercial and regulatory presence in the US market. The scale of US cardiovascular disease burden anchors a domestic stent market large enough to sustain multiple competing platforms simultaneously even as international competition from manufacturers such as MicroPort Coronary intensifies.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. China and India represent the two largest national markets within the region, driven by rising cardiovascular disease incidence and MicroPort Coronary's expanding domestic and international manufacturing scale, confirmed by its October 2025 milestone of 10 million cumulative global shipments and implantations. Medtronic also expanded its Resolute Onyx DES platform into Asia with CoreWire technology, reinforcing established manufacturer investment in the region's growth.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, France, and the United Kingdom represent the three largest national markets within Europe. Boston Scientific launched its Synergy XD Bioabsorbable Polymer DES in Europe, and Medtronic received CE Mark clearance for its improved Resolute Onyx polymer formulation in the region. The result is steady rather than rapid growth, shaped more by national health system reimbursement negotiation than by underlying patient demand.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national markets within the region, with private hospital networks driving early adoption of next-generation DES platforms among higher-income patients. The ongoing Iran-US sanctions and the resulting Strait of Hormuz shipping disruption have raised freight and import costs for the specialised cobalt-chromium and platinum-chromium alloy components that Latin American device distributors depend on, an effect expected to run through 2026 and slow intravascular stent adoption beyond Brazil's and Mexico's main urban centres.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial markets within the region. Saudi Arabia's expanding private hospital network and the UAE's regional distribution hubs represent the primary investment centres for intravascular stent adoption. Saudi Arabia is the most established market on the continent, while the Gulf states outside it are still building the interventional cardiology infrastructure needed to support advanced DES platforms at scale.